New therapeutic schedule for prostatic cancer-3 cells with ET-1 RNAi and Endostar

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 23, 2014, Pages 10079-10083

  Zhang, Hao Jie ^a   Qian, Wei Qing ^a   Chen, Ran ^a   Sun, Zhong Quan ^a   Song, Jian Da ^a   Sheng, Lu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Endostar; ET 1 RNAi; Invasion; PC 3 cells; Proliferation

Indexed keywords

CASP3 PROTEIN, HUMAN; CASPASE 3; ENDOSTAR PROTEIN; ENDOSTATIN; ENDOTHELIN 1; GELATINASE A; GELATINASE B; MESSENGER RNA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSTATINS; ENDOTHELIN-1; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84921749020     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.23.10079     Document Type: Article

References (47)

1. Ali H, Loizidou M, Dashwood M, et al (2000). Stimulation of colorectal cancer cell line growth by ET-1 and its inhibition by ET (A) antagonists. Gut, 47, 685-8.
2. Bagnato A, Rosano L (2012). Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. Curr Oncol, 19, 36-8.
3. De Jesus-Gonzalez N, Robinson E, Penchev R, et al (2012). Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens, 25, 1118-6.
4. Dhanabal M, Ramchandran R, Waterman MJ, et al (1999). Endostatin induces endothelial cell apoptosis. J Biol Chem, 274, 11721-6.
5. Dong X-P, Xiao T-H, Dong H, et al (2013). Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice. APJCP, 14, 3079-3083.
6. Fiorentini C, Bodei S, Bedussi F, et al (2014). GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res, 323, 100-11.
7. Folkman J (2006). Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 312, 594-607.
8. Ha NH, Nair VS, Reddy DN, et al (2011). Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res, 71, 7259-69.
9. Hinsley EE, Kumar S, Hunter KD, et al (2012). Endothelin-1 stimulates oral fibroblasts to promote oral cancer invasion. Life Sci, 91, 557-561.
10. Hsu JY, Pfahl M (1998). ET-1 expression and growth inhibition of prostate cancer cells: a retinoid target with novel specificity. Cancer Res, 58, 4817-22.
11. Irani S, Salajegheh A, Smith RA, et al (2014). A review of the profile of endothelin axis in cancer and its management. Crit Rev Oncol Hematol, 89, 314-21.
12. Johan Dixelius, Helena Larsson, Takako Sasaki, et al (2000). Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood, 95, 3403-11.
13. Kalles V, Zografos GC, Provatopoulou X, et al (2012). Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis. Tumour Biol, 33, 1231-6.
14. Kim YM, Jang JW, Lee OH, et al (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res, 60, 5410-3.
15. Leon J, Casado J, Jimenez Ruiz SM, et al (2014). Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-kappabeta. J Pineal Res, 56, 415-26.
16. Li Z, Zhang LJ, Zhang HR, et al (2014). Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance. Asian Pac J Cancer Prev, 15, 5181-6.
17. Ling L, Maguire JJ, Davenport AP (2013). Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br J Pharmacol, 168, 283-95.
18. Ling Y, Yang Y, Lu N, et al (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361, 79-84.
19. Liu C, Xu P, Chen D, et al (2013). Roles of autophagy-related genes Beclin-1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia. Biomed Rep, 1, 855-60.
20. Lu N, Ling Y, Gao Y, et al (2008). Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood), 233, 1013-8.
21. Maffei R, Bulgarelli J, Fiorcari S, et al (2014). Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS One, 9, 1-13.
22. 3. Basic&Clinical Medicine, 27, 772-5.
23. Ni Q, Ji H, Zhao Z, et al (2009). Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol, 614, 1-6.
24. Nyberg P, Heikkila P, Sorsa T, et al (2003). Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2,-9, and-13. J Biol Chem, 278, 22404-8.
25. O'Reilly MS, Boehm T, Shing Y, et al (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-9.
26. Puzovic V, Brcic I, Ranogajec I, et al (2014). Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients. Neoplasma, 61, 439-9.
27. Rosano L, Spinella F, Bagnato A (2013). Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 13, 637-51.
28. Rotondo S, Menard J, Durlach A, et al (2012). Endothelin-1 and receptor A: predictive value for biochemical relapse on patients with advanced and metastatic prostate cancer. Prog Urol, 22, 38-4.
29. Shao N, Wang Y, Jiang WY, et al (2013). Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. Int J Cancer, 133, 1743-8.
30. Spinella F, Caprara V, Cianfrocca R, et al (2014). The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis, 35, 840-8.
31. Stassi G, Todaro M, Zerilli M, et al (2003). Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res, 63, 6784-7.
32. Sudhakar A, Sugimoto H, Yang C, et al (2003). Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA, 100, 4766-6.
33. Szarvas T, Laszlo V, Vom Dorp F, et al (2012). Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. Int J Cancer, 130, 2922-9.
34. Tamkus D, Sikorskii A, Gallo KA, et al (2013). Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence. ISRN Oncol, 2013, 385-98.
35. Te Velde EA, Reijerkerk A, Brandsma D, et al (2005). Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer, 92, 729-35.
36. Wang R, Lohr CV, Fischer K, et al (2013a). Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer. Int J Cancer, 132, 1004-9.
37. Wang YB, Liu JH, Song ZM (2013b). Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803. Biomed Rep, 1, 77-80.
38. Wang YB, Liu JH, Song ZM (2013c). Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803. Biomed Rep, 1, 77-9.
39. Wei HM, Qin SK, Yin XJ, et al (2010). Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice. Nan Fang Yi Ke Da Xue Xue Bao, 30, 1509-13 (in Chinese).
40. Wu X, Zheng J, Zhu J, et al (2001). Inhibitory effect of antisense VEGF121 and endostatin genes transfection on tumor growth and metastasis of human giant cell lung cancer. Zhongguo Fei Ai Za Zhi, 4, 83-7.
41. Wynder EL, Mabuchi K, Whitmore WF, Jr. (1971). Epidemiology of cancer of the prostate. Cancer, 28, 344-60.
42. Xu YF, Zhu LP, Hu B, et al (2007). A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther, 14, 151-7.
43. Xue Xue, Song You, Liang. X (2010). Chemotherapertic resistance of cancer and its related gene therapeutic drugs. Chinese J Med Chem, 20, 460-7.
44. Yokoyama Y, Ramakrishnan S (2007). Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer, 121, 2402-9.
45. Zhang L-P, Liao X-Y, Xu Y-M, et al (2013). Efficacy and safety of endostar®combined with chemotherapy in patients with advanced soft tissue sarcomas. Asian Pac J Cancer Prev, 14, 4255-5.
46. Zhang Y, Ge W, Zhao J, et al (2009). The effect of endostatin and radiotherapy on human lung cancer cell line a549 and the impact of hif-1 expression after therapy. Zhongguo Fei Ai Za Zhi, 12, 33-7.
47. Zhou WQ, Yin HL, Zhang ZY, et al (2008). Expression of VEGF in prostate cancer and its correlation with ET-1. Zhonghua Nan Ke Xue, 14, 987-92.